Abstract 219P
Background
The rate of incidence for advanced thymoma is low. Reports on the promising efficacy and low toxicity of platinum-based chemotherapy in advanced thymoma are lacking. In addition, correlation for chemotherapy efficacy and safety among different subtypes of thymoma remains unexplored.
Methods
We analyzed the efficacy and safety of platinum-based chemotherapy as the first-line treatment for different types of thymoma patients. The objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse event results were obtained. Cox proportional hazards regression was analyzed to determine the factors independently associated with PFS.
Results
The study evaluated 71 thymoma patients treated at the Zhejiang Cancer Hospital between January 2009 and March 2022. The ORR for advanced thymoma patients was 36.6%. PFS and OS for the whole cohort were 17.7 and 59.8 months, respectively. The difference in PFS between A-B2 (including A, AB, B1, and B2 subtypes) and B3 thymoma patients was significant (28.2 vs. 10.7 months, P = 0.015). Cox analysis results indicated that thymoma patient subtype was the only factor influencing the PFS.
Conclusions
Advanced thymoma patients can benefit from platinum-based chemotherapy. B3 thymoma patients demonstrated inferior efficacy of platinum-based chemotherapy used as the first-line treatment compared to A-B2 patients.
Legal entity responsible for the study
The authors.
Funding
Foundation of CSCO-Shiyao (Y-SY201901-0068, to Zhengbo Song).
Disclosure
All authors have declared no conflicts of interest.